Staidson (300204.SZ): Bojianing (pomiteplase alfa for injection) application for additional indication new drug clinical trial is accepted
Staidson (300204.SZ) announced that recently, its subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. ("Beijietai") received the Acceptance Notice, an administrative licensing document from the National Medical Products Administration. The National Medical Products Administration agreed to accept the clinical trial application submitted by Beijietai for the additional indication of pomiteplase alfa for injection. The acceptance number is:
CXSL2601019, application stage: clinical; indication: treatment of major surgical bleeding.
Staidson (300204.SZ) announced that recently, its subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. (hereinafter referred to as "Beijietai") received the Acceptance Notice, an administrative licensing document from the National Medical Products Administration. The National Medical Products Administration agreed to accept the clinical trial application submitted by Beijietai for the additional indication of pomiteplase alfa for injection. The acceptance number is:
CXSL2601019, application stage: clinical; indication: treatment of major surgical bleeding.
Related Articles
CHAOJU EYE CARE (02219) repurchased 300,000 shares for approximately HK$734,600 on September 18.
HAIER SMARTHOME (06690) repurchased 300,000 shares for HK$6.1979 million on September 18.
WANT WANT CHINA (00151) repurchased 3.5 million shares for HK$9.8732 million on September 18.
CHAOJU EYE CARE (02219) repurchased 300,000 shares for approximately HK$734,600 on September 18.
HAIER SMARTHOME (06690) repurchased 300,000 shares for HK$6.1979 million on September 18.
WANT WANT CHINA (00151) repurchased 3.5 million shares for HK$9.8732 million on September 18.
RECOMMEND
